Medical Genetics Unit, S. Orsola-Malpighi Hospital, Bologna, Italy.
Instituto de Biomedicina de Valencia of the CSIC, Valencia, Spain.
Ann Clin Transl Neurol. 2019 Aug;6(8):1533-1540. doi: 10.1002/acn3.50821. Epub 2019 Jul 19.
In 2015-2016, we and others reported ALDH18A1 mutations causing dominant (SPG9A) or recessive (SPG9B) spastic paraplegia. In vitro production of the ALDH18A1 product, Δ -pyrroline-5-carboxylate synthetase (P5CS), appeared necessary for cracking SPG9 disease-causing mechanisms. We now describe a baculovirus-insect cell system that yields mgs of pure human P5CS and that has proven highly valuable with two novel P5CS mutations reported here in new SPG9B patients. We conclude that both mutations are disease-causing, that SPG9B associates with partial P5CS deficiency and that it is clinically more severe than SPG9A, as reflected in onset age, disability, cognitive status, growth, and dysmorphic traits.
在 2015-2016 年,我们和其他人报道了 ALDH18A1 突变导致显性(SPG9A)或隐性(SPG9B)痉挛性截瘫。体外产生 ALDH18A1 产物 δ -吡咯啉-5-羧酸合成酶(P5CS)似乎对于破解 SPG9 致病机制是必要的。我们现在描述了一个杆状病毒-昆虫细胞系统,可以产生毫克级的纯人 P5CS,并且已经被证明非常有价值,因为这里报道了两个新的 SPG9B 患者的新型 P5CS 突变。我们得出结论,这两个突变都是致病的,SPG9B 与部分 P5CS 缺乏有关,并且它比 SPG9A 更严重,表现在发病年龄、残疾、认知状态、生长和畸形特征上。